Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, JapanCorrespondence: Tetsuya MitsudomiKindai University Faculty of Medicine, Division of Thoracic Surgery, Department of Surgery, 377-2 Ohno-Higash...
Guardado en:
Autores principales: | Fujino T, Suda K, Mitsudomi T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f984ebd2259242cf97186c7a243e1fc5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan AC, et al.
Publicado: (2021) -
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo MZ, et al.
Publicado: (2021) -
Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa
por: Franciscus C. Vermeer, et al.
Publicado: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021) -
Case Report: A Synonymous Mutation in NF1 Located at the Non-canonical Splicing Site Leading to Exon 45 Skipping
por: Pengzhen Jin, et al.
Publicado: (2021)